相关实验视频

Updated: May 26, 2025

Robot-Assisted Radical Antegrade Modular Pancreatosplenectomy Including Resection and Reconstruction of the Spleno-Mesenteric Junction

Robot-Assisted Radical Antegrade Modular Pancreatosplenectomy Including Resection and Reconstruction of the Spleno-Mesenteric Junction

Published on: January 3, 2020

一线Sugemalimab加化学治疗晚期胃癌:GEMSTONE-303随机临床试验

Xiaotian Zhang¹, Jufeng Wang², Gang Wang³

¹State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, China.

|February 24, 2025

概括

在晚期胃癌患者中,sugemalimab加化疗显著改善了整体存活率和无进展存活率. 在GEMSTONE-303试验中,这种组合治疗显示出可控的安全性.

科学领域:

癌症学
免疫疗法
消化道癌症

背景情况:

胃癌是全球癌症相关死亡的主要原因.
在早期的胃癌研究中,sugemalimab是一种抗PD- L1抗体.
在GEMSTONE-303试验中,研究了苏格马利马布与晚期胃癌的化疗联合治疗.

研究的目的:

评估Sugemalib加 capecitabine和oxaliplatin (CAPOX) 与安慰剂加 CAPOX 的疗效.
评估无法切除的,局部晚期或转移的胃/食道结腺癌的第一线治疗方法.
专注于PD- L1综合阳性得分 (CPS) 为5或以上的患者.

主要方法:

第三阶段,随机双盲,安慰剂对照试验 (GEMSTONE-303).
479名患者患有局部晚期/ 转移性胃腺癌或GEJ,PD- L1 CPS ≥5.
治疗组: 苏格马利马布 (1200 mg IV q3w) + 卡波克斯与安慰剂+卡波克斯.

主要成果:

苏格玛利马布显著改善了整体存活率 (中位数为15. 6个月;HR为0. 75;P=. 006).
无进展的存活期也显著改善 (中位数为7. 6个月;HR为0. 66;P<. 001).
与治疗相关的≥3级不良事件相似 (53. 9%与50. 6%).

结论:

在以前未接受过治疗的晚期胃癌患者中,Sugemalimab加CAPOX具有显著的生存益处.
这种组合显示出可管理的安全性.
这种治疗方案代表了PD-L1阳性胃癌的潜在新标准治疗.

更多相关视频

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...